Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'RESISTANT SCHIZOPHRENIA' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 168 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. McCall, WV
      Electroconvulsive thera in the era of modern psychopharmacology

      INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
    2. Risch, SC; McGurk, S; Horner, MD; Nahas, Z; Owens, SD; Molloy, M; Gilliard, C; Christie, S; Markowitz, JS; DeVane, CL; Mintzer, J; George, MS
      A double-blind placebo-controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient: Functional MRI correlates

      NEUROCASE
    3. Chanpattana, W; Chakrabhand, MLS
      Factors influencing treatment frequency of continuation ECT in schizophrenia

      JOURNAL OF ECT
    4. Hirose, S; Ashby, CR; Mills, MJ
      Effectiveness of ECT combined with risperidone against aggression in schizophrenia

      JOURNAL OF ECT
    5. Kennedy, A; Jain, S; Vinogradov, S
      Atypical antipsychotics for schizophrenia: Their collective role and comparative profiles

      FORMULARY
    6. Jones, A
      Hospital care pathways for patients with schizophrenia

      JOURNAL OF CLINICAL NURSING
    7. Barnes, TRE; Joyce, EM
      Antipsychotic drug treatment: recent advances

      CURRENT OPINION IN PSYCHIATRY
    8. Silver, H; Shlomo, M
      Perception of facial emotions in chronic schizophrenia does not correlate with negative symptoms but correlates with cognitive and motor dysfunction

      SCHIZOPHRENIA RESEARCH
    9. Belsham, B
      Glutamate and its role in psychiatric illness

      HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL
    10. Breitenstein, C; Van Lancker, D; Daum, I; Waters, CH
      Impaired perception of vocal emotions in Parkinson's disease: Influence ofspeech time processing and executive functioning

      BRAIN AND COGNITION
    11. Ozdemir, V; Kalow, W; Posner, P; Collins, EJ; Kennedy, JL; Tang, BK; Albers, LJ; Reist, C; Roy, R; Walkes, W; Afra, P
      CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite norclozapine steady-state concentration in patients with schizophrenia

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    12. Lindenmayer, JP; Volavka, J; Lieberman, J; Sheitman, B; Citrome, L; Chakos, M; Czobor, P; Parker, B; Iskander, A
      Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: An open-label, prospective trial

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    13. Glick, ID; Lemmens, P; Vester-Blokland, E
      Treatment of the symptoms of schizophrenia: a combined analysis of double-blind studies comparing risperidone with haloperidol and other antipsychotic agents

      INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
    14. Kane, J
      Progress defined - short-term efficacy, long-term effectiveness

      INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
    15. Iwanami, A; Okajima, Y; Isono, H; Shinoda, J; Kasai, K; Hata, A; Fukuda, M; Nakagome, K; Kamijima, K
      Effects of risperidone on event-related potentials in schizophrenic patients

      PHARMACOPSYCHIATRY
    16. Kapur, S; Remington, G
      Atypical antipsychotics: New directions and new challenges in the treatment of schizophrenia

      ANNUAL REVIEW OF MEDICINE
    17. Bhana, N; Foster, RH; Olney, R; Plosker, GL
      Olanzapine - An updated review of its use in the management of schizophrenia

      DRUGS
    18. Miller, DD; Andreasen, NC; O'Leary, DS; Watkins, GL; Ponto, LLB; Hichwa, RD
      Comparison of the effects of risperidone and haloperidol on regional cerebral blood flow in schizophrenia

      BIOLOGICAL PSYCHIATRY
    19. Green, MF; Braff, DL
      Translating the basic and clinical cognitive neuroscience of schizophreniato drug development and clinical trials of antipsychotic medications

      BIOLOGICAL PSYCHIATRY
    20. Goff, DC; Coyle, JT
      The emerging role of glutamate in the pathophysiology and treatment of schizophrenia

      AMERICAN JOURNAL OF PSYCHIATRY
    21. Azorin, JM; Spiegel, R; Remington, G; Vanelle, JM; Pere, JJ; Giguere, M; Bourdeix, I
      A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia

      AMERICAN JOURNAL OF PSYCHIATRY
    22. Sernyak, MJ; Desai, R; Stolar, M; Rosenheck, R
      Impact of clozapine on completed suicide

      AMERICAN JOURNAL OF PSYCHIATRY
    23. Harvey, PD; Keefe, RSE
      Studies of cognitive change in patients with schizophrenia following novelantipsychotic treatment

      AMERICAN JOURNAL OF PSYCHIATRY
    24. Heresco-Levy, U
      N-methyl-D-aspartate (NMDA) receptor-based treatment approaches in schizophrenia: the first decade

      INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
    25. Hellewell, JSE; Gerlach, JES
      Opportunities and challenges presented by the new generation antipsychotics

      INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE
    26. Stip, E
      Novel antipsychotics: issues and controversies. Typicality of atypical antipsychotics

      JOURNAL OF PSYCHIATRY & NEUROSCIENCE
    27. Meltzer, HY; Anand, R; Alphs, L
      Reducing suicide risk in schizophrenia - Focus on the role of clozapine

      CNS DRUGS
    28. Procyshyn, RM; Thompson, D; Tse, G
      Pharmacoeconomics of clozapine, risperidone and olanzapine - A review of the literature

      CNS DRUGS
    29. Edgell, ET; Andersen, SW; Johnstone, BM; Dulisse, B; Revicki, D; Breier, A
      Olanzapine versus risperidone - A prospective comparison of clinical and economic outcomes in schizophrenia

      PHARMACOECONOMICS
    30. Lindstrom, E; Bingefors, K
      Patient compliance with drug therapy in schizophrenia - Economic and clinical issues

      PHARMACOECONOMICS
    31. Worrel, JA; Marken, PA; Beckman, SE; Ruehter, VL
      Atypical antipsychotic agents: A critical review

      AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
    32. Adams, C; Wilson, P; Gilbody, S; Bagnall, AM; Lewis, R
      Drug treatments for schizophrenia

      QUALITY IN HEALTH CARE
    33. Marder, SR
      Newer antipsychotics

      CURRENT OPINION IN PSYCHIATRY
    34. Frangou, S; Lewis, M
      Atypical antipsychotics in ordinary clinical practice: a pharmaco-epidemiologic survey in a south London service

      EUROPEAN PSYCHIATRY
    35. Weiser, M; Shneider-Beeri, M; Nakash, N; Brill, N; Bawnik, O; Reiss, S; Hocherman, S; Davidson, M
      Improvement in cognition associated with novel antipsychotic drugs: a direct drug effect or reduction of EPS?

      SCHIZOPHRENIA RESEARCH
    36. Sheitman, BB; Murray, MG; Snyder, JA; Silva, S; Goldman, R; Chakos, M; Volavka, J; Lieberman, JA
      IQ scores of treatment-resistant schizophrenia patients before and after the onset of the illness

      SCHIZOPHRENIA RESEARCH
    37. Voruganti, L; Cortese, L; Oyewumi, L; Cernovsky, Z; Zirul, S; Awad, A
      Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life

      SCHIZOPHRENIA RESEARCH
    38. Carpenter, WT; Conley, R; Kirkpatrick, B
      On schizophrenia and new generation drugs

      NEUROPSYCHOPHARMACOLOGY
    39. Meltzer, H; Kostakaglu, E; Lee, M
      Response: Negative symptoms redux

      NEUROPSYCHOPHARMACOLOGY
    40. Davidson, M; Harvey, PD; Vervarcke, J; Gagiano, CA; De Hooge, JD; Bray, G; Dose, M; Barak, Y; Haushofer, M
      A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis

      INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY
    41. Erlandsen, C
      Clozapine for schizophrenia - Clinical effect, financial considerations, and quality requirements

      NORDIC JOURNAL OF PSYCHIATRY
    42. Rivas-Vazquez, RA; Blais, MA; Rey, GJ; Rivas-Vazquez, AA
      Atypical antipsychotic medications: Pharmacological profiles and psychological implications

      PROFESSIONAL PSYCHOLOGY-RESEARCH AND PRACTICE
    43. Chong, SA; Remington, G
      Clozapine augmentation: Safety and efficacy

      SCHIZOPHRENIA BULLETIN
    44. Lerner, V; Chudakova, B; Kravets, S; Polyakova, I
      Combined use of risperidone and olazapine in the treatment of patients with resistant schizophrenia: A preliminary case series report

      CLINICAL NEUROPHARMACOLOGY
    45. Angelucci, F; Mathe, AA; Aloe, L
      Brain-derived neurotrophic factor and tyrosine kinase receptor TrkB in ratbrain are significantly altered after haloperidol and risperidone administration

      JOURNAL OF NEUROSCIENCE RESEARCH
    46. Taylor, DM; Duncan-McConnell, D
      Refractory schizophrenia and atypical antipsychotics

      JOURNAL OF PSYCHOPHARMACOLOGY
    47. Silver, H; Barash, I; Aharon, N; Kaplan, A; Poyurovsky, M
      Fluvoxamine augmentation of antipsychotics improves negative symptoms in psychotic chronic schizophrenic patients: a placebo-controlled study

      INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
    48. Emsley, RA; Raniwalla, J; Bailey, PJ; Jones, AM
      A comparison of the effects of quetiapine ('Seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment

      INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
    49. Masaguer, CF; Ravina, E; Fontenla, JA; Brea, J; Tristan, H; Loza, MI
      Butyrophenone analogues in the carbazole series as potential atypical antipsychotics: synthesis and determination of affinities at D-2, 5-HT2A, 5-HT2B and 5-HT2C receptors

      EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
    50. Sharif, ZA; Raza, A; Ratakonda, SS
      Comparative efficacy of risperidone and clozapine in the treatment of patients with refractory schizophrenia or schizoaffective disorder: A retrospective analysis

      JOURNAL OF CLINICAL PSYCHIATRY
    51. Dossenbach, MRK; Beuzen, JN; Avnon, M; Belmaker, RH; Elizur, A; Mark, M; Munitz, H; Schneidman, M; Shoshani, D; Kratky, P; Grundy, SL; Tollefson, GD
      The effectiveness of olanzapine in treatment-refractory schizophrenia whenpatients are nonresponsive to or unable to tolerate clozapine

      CLINICAL THERAPEUTICS
    52. Harvey, PD
      Management of schizophrenia with cognitive impairment

      PSYCHIATRIC ANNALS
    53. Lindenmayer, JP
      Treatment refractory schizophrenia

      PSYCHIATRIC QUARTERLY
    54. Keltner, NL; Coffeen, H; Johnson, JE
      Atypical antipsychotic drugs: Part II

      PERSPECTIVES IN PSYCHIATRIC CARE
    55. Schulz, SC
      New antipsychotic medications: More than old wine and new bottles

      BULLETIN OF THE MENNINGER CLINIC
    56. Buckley, PF
      Comprehensive disease management for schizophrenia

      DRUGS OF TODAY
    57. Masellis, M; Basile, VS; Ozdemir, V; Meltzer, HY; Macciardi, FM; Kennedy, JL
      Pharmacogenetics of antipsychotic treatment: Lessons learned from clozapine

      BIOLOGICAL PSYCHIATRY
    58. Velakoulis, D; Wood, SJ; McGorry, PD; Pantelis, C
      Evidence for progression of brain structural abnormalities in schizophrenia: beyond the neurodevelopmental model

      AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY
    59. Remington, G; Kapur, S
      Atypical antipsychotics: are some more atypical than others?

      PSYCHOPHARMACOLOGY
    60. Amin, S
      Cost-effectiveness of atypical antipsychotics in chronic schizophrenia

      HOSPITAL MEDICINE
    61. Duncan, GE; Zorn, S; Lieberman, JA
      Mechanisms of typical and atypical antipsychotic drug action in relation to dopamine and NMDA receptor hypofunction hypotheses of schizophrenia

      MOLECULAR PSYCHIATRY
    62. Remington, G; Chong, SA
      Conventional versus novel antipsychotics: changing concepts and clinical implications

      JOURNAL OF PSYCHIATRY & NEUROSCIENCE
    63. Keegan, DL; Albright, P; Petersen, T
      Long-term healthcare resource utilisation and costs before and after initiation of risperidone treatment in patients with chronic schizophrenia

      CLINICAL DRUG INVESTIGATION
    64. Foster, RH; Goa, KL
      Olanzapine - A pharmacoeconomic review of its use in schizophrenia

      PHARMACOECONOMICS
    65. Chanpattana, W; Chakrabhand, S; Sackeim, HA; Kitaroonchai, W; Kongsakon, R; Techakasem, P; Buppanharun, W; Tuntirungsee, Y; Kirdcharoen, N
      Continuation ECT in treatment-resistant schizophrenia: A controlled study

      JOURNAL OF ECT
    66. Chanpattana, W; Chakrabhand, MLS; Kongsakon, R; Techakasem, P; Buppanharun, W
      Short-term effect of combined ECT and neuroleptic therapy in treatment-resistant schizophrenia

      JOURNAL OF ECT
    67. Chanpattana, W
      Maintenance ECT in mentally retarded, treatment-resistant schizoprenic patients

      JOURNAL OF ECT
    68. Pinals, DA; Buckley, PF
      Novel antipsychotic agents and their implications for forensic psychiatry

      JOURNAL OF THE AMERICAN ACADEMY OF PSYCHIATRY AND THE LAW
    69. Jeste, DV; Rockwell, E; Harris, MJ; Lohr, JB; Lacro, J
      Conventional vs. newer antipsychotics in elderly patients

      AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
    70. Krystal, JH; D'Souza, DC; Madonick, S; Petrakis, IL
      Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients

      SCHIZOPHRENIA RESEARCH
    71. Revicki, DA
      Pharmacoeconomic studies of atypical antipsychotic drugs for the treatmentof schizophrenia

      SCHIZOPHRENIA RESEARCH
    72. Meltzer, HY
      The role of serotonin in antipsychotic drug action

      NEUROPSYCHOPHARMACOLOGY
    73. Rund, BR
      How do neuroleptics affect cognitive dysfunctions in schizophrenia?

      NORDIC JOURNAL OF PSYCHIATRY
    74. Kissling, W; Hoffler, J; Seemann, U; Muller, P; Ruther, E; Trenckmann, U; Uber, A; Von der Schulenburg, JMG; Glaser, P; Glaser, T; Mast, O; Schmidt, D
      Direct and indirect costs of schizophrenia

      FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE
    75. Dittert, S; Soyka, M; Winter, C; Moller, HJ
      Cognition and driving ability of schizophrenic patients on risperidone versus haloperidol

      FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE
    76. Dursun, SM; Gardner, DM; Bird, DC; Flinn, J
      Olanzapine for patients with treatment-resistant schizophrenia: A naturalistic case-series outcome study

      CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE
    77. Blin, O
      A comparative review of new antipsychotics

      CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE
    78. Meltzer, HY; McGurk, SR
      The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia

      SCHIZOPHRENIA BULLETIN
    79. Dawkins, K; Lieberman, JA; Lebowitz, BD; Hsiao, JK
      Antipsychotics: Past and future - National Institute of Mental Health Division of Services and Intervention Research Workshop, July 14, 1998

      SCHIZOPHRENIA BULLETIN
    80. Campbell, M; Young, PI; Bateman, DN; Smith, JM; Thomas, SHL
      The use of atypical antipsychotics in the management of schizophrenia

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    81. Sanders, RD; Mossman, D
      An open trial of olanzapine in patients with treatment-refractory psychoses

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    82. Szegedi, A; Anghelescu, I; Wiesner, J; Schlegel, S; Weigmann, H; Hartter, S; Hiemke, C; Wetzel, H
      Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: Drug monitoring and tolerability data from a prospective clinical trial

      PHARMACOPSYCHIATRY
    83. Miller, AL; Chiles, JA; Chiles, JK; Crismon, ML; Rush, AJ; Shon, SP
      The Texas Medication Algorithm Project (TMAP) schizophrenia algorithms

      JOURNAL OF CLINICAL PSYCHIATRY
    84. Meltzer, HY
      Outcome in schizophrenia: Beyond symptom reduction

      JOURNAL OF CLINICAL PSYCHIATRY
    85. Fleischhacker, WW
      Clozapine: A comparison with other novel antipsychotics

      JOURNAL OF CLINICAL PSYCHIATRY
    86. Stahl, SM
      Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials

      JOURNAL OF CLINICAL PSYCHIATRY
    87. Revicki, DA
      Pharmacoeconomic evaluation of treatments for refractory schizophrenia: Clozapine-related studies

      JOURNAL OF CLINICAL PSYCHIATRY
    88. Buckley, PF
      New antipsychotic agents: Emerging clinical profiles

      JOURNAL OF CLINICAL PSYCHIATRY
    89. Meltzer, HY; Park, S; Kessler, R
      Cognition, schizophrenia, and the atypical antipsychotic drugs

      PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
    90. Jeste, DV; Rockwell, E; Harris, MJ; Lohr, JB; Lacro, J
      Conventional vs. newer antipsychotics in elderly patients

      BULLETIN OF THE MENNINGER CLINIC
    91. Ravina, E; Negreira, J; Cid, J; Masaguer, CP; Rosa, E; Rivas, ME; Fontenla, JA; Loza, MI; Tristan, H; Cadavid, MI; Sanz, F; Lozoya, E; Carotti, A; Carrieri, A
      Conformationally constrained butyrophenones with mixed dopaminergic (D-2) and serotoninergic (5-HT2A, 5-HT2C) affinities: Synthesis, pharmacology, 3D-QSAR, and molecular modeling of (aminoalkyl)benzo- and -thienocycloalkanones as putative atypical antipsychotics

      JOURNAL OF MEDICINAL CHEMISTRY
    92. Masaguer, CF; Casariego, I; Ravina, E
      Conformationally restricted butyrophenones with mixed dopaminergic (D-2) and serotoninergic (5-MT2A) affinities. Synthesis of 5-aminoethyl- and 6-aminomethyl-4-oxotetrahydroindoles as potential atypical antipsychotics

      CHEMICAL & PHARMACEUTICAL BULLETIN
    93. Kane, JM
      Pharmacologic treatment of schizophrenia

      BIOLOGICAL PSYCHIATRY
    94. Breier, A; Hamilton, SH
      Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia

      BIOLOGICAL PSYCHIATRY
    95. Carpenter, WT; Buchanan, RW; Kirkpatrick, B; Breier, AF
      Diazepam treatment of early signs of exacerbation in schizophrenia

      AMERICAN JOURNAL OF PSYCHIATRY
    96. Simpson, GM; Josiassen, RC; Stanilla, JK; de Leon, J; Nair, C; Abraham, G; Odom-White, A; Turner, RM
      Double-blind study of clozapine dose response in chronic schizophrenia

      AMERICAN JOURNAL OF PSYCHIATRY
    97. Rund, BR; Borg, NE
      Cognitive deficits and cognitive training in schizophrenic patients: a review

      ACTA PSYCHIATRICA SCANDINAVICA
    98. ISKEDJIAN M; HUX M; REMINGTON GJ
      THE CANADIAN EXPERIENCE WITH RISPERIDONE FOR THE TREATMENT OF SCHIZOPHRENIA - AN OVERVIEW

      Journal of psychiatry & neuroscience
    99. MORRIS S; HOGAN T; MCGUIRE A
      THE COST-EFFECTIVENESS OF CLOZAPINE - A SURVEY OF THE LITERATURE

      Clinical drug investigation
    100. FOSTER RH; GOA KL
      RISPERIDONE - A PHARMACOECONOMIC REVIEW OF ITS USE IN SCHIZOPHRENIA

      PharmacoEconomics


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 10/12/19 alle ore 01:45:39